How to dose MOTS-c

The MOTS-c pen from Body Pharm is titrated upwards from the lowest setting, rather than starting out on a fixed research dose. Begin with 0.2 mg for the first two weeks, so that the body gets used to the product, and then move up in 0.2 mg steps (0.4 mg, 0.6 mg, 0.8 mg, 1 mg) no more often than every two weeks, and only if your energy is good and the previous dose is well tolerated. If after a dose you notice tiredness or you suffer a crash, stay on that dose until you feel normal on it before going any higher. Administration is by the subcutaneous route, using 30–32 G, 4–6 mm insulin needles [1][4]. As of 2026 there is no completed, peer-reviewed phase 1 or phase 2 human study published with a full dosing table, so that every one of the parameters set out below reflects Body Pharm's product guidance together with the rodent work and clinic practice, not an authorised therapeutic regimen [5].

MOTS-c dosing: the essentials

• Start with 0.2 mg for the first two weeks, so that the body gets used to the product, and then titrate in 0.2 mg steps (0.4, 0.6, 0.8, 1 mg) no more often than every two weeks
• Move up only if your energy is good and the current dose is fully tolerated; if a dose brings on tiredness or a crash, stay there until you feel normal on it before going any higher
• The typical sign that you have gone up too fast is the post-workout crash: energy during the session and then, 3–4 hours later, a sharp drop; that means the body has not yet adjusted to the dose
• The usual practice is to inject around 30 minutes before training, so that the energy arrives during the session itself
• AMPK activation persists for 48–72 hours after the injection, so that dosing every day is redundant and may blunt the effect
• Subcutaneous injection into the abdomen or the thigh with 30–32 G needles is the standard route of administration
• MOTS-c is a research peptide with no marketing authorisation; every one of the dosing parameters here is a research extrapolation and Body Pharm product guidance, not medical advice

The titration at a glance

The two-week minimum per step is a floor, not a target. If after a dose you notice tiredness or you suffer a crash, stay on it until you feel normal on that dose, for however many weeks that takes, before you even consider the next step. MOTS-c is a research peptide with no marketing authorisation [5].

What MOTS-c is and why dosing matters

MOTS-c is a 16-amino-acid peptide of mitochondrial origin, encoded by the mitochondrial 12S rRNA gene, with a molecular weight of around 2,174 Da [2]. Lee and colleagues first characterised it in 2015 (Cell Metabolism) as a systemic regulator of metabolic homeostasis in mouse models. It acts through the AMPK (adenosine monophosphate-activated protein kinase) pathway and it mimics an energy-deficit signal, similar to the one that exercise or caloric restriction produces [2].

From a mechanistic point of view, MOTS-c interferes with the metabolism of methionine and of purines within the folate cycle. That raises the pool of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) and triggers the phosphorylation of AMPK. That cascade upregulates mitochondrial biogenesis, transport via GLUT4 (glucose transporter type 4) and fatty acid oxidation in skeletal muscle [2]. The signal is a higher-order, metabolic one, and it is not receptor-mediated in the classic sense of a GPCR (G-protein-coupled receptor), which is why the logic of dosing differs from that of peptides such as the GHRH (growth hormone-releasing hormone) analogues.

Why precision matters

The AMPK response depends on the dose and on the frequency alike. Too little produces no measurable effect at all; too much, and too fast, produces the crash pattern that researchers have described: a strong surge of energy followed by a deep drop hours later, as the system overcorrects. A slow upward titration lets the body adapt to each rung of the energy-stress signal before the next increase comes. Continuous, high-frequency administration runs the risk of blunting precisely the energy-stress signalling that makes the peptide useful. AMPK is a sensor that adapts to chronic activation, so that repeated exposure without any rest windows dulls the metabolic signal.

That is why the practical protocol starts as low as 0.2 mg and moves up in small 0.2 mg steps: each step is taken only once the previous one feels comfortable, so that you find the level that your body tolerates instead of overshooting it [1].

As of 2026 no large human RCT (randomised controlled trial) on MOTS-c has been completed and published with full dosing tables, so that all of the parameters discussed here are extrapolated from preclinical work and from clinic practice [2][3][4]. The same research-use caveats apply to the whole group of mitochondrial peptides, including NAD+ dosing and tissue-repair substances such as GHK-Cu.

The Body Pharm titration protocol at a glance

The approach Body Pharm takes has everyone start low and go up slowly. You begin with 0.2 mg per injection for the first two weeks, purely so that the body gets used to the product, and then go up in 0.2 mg steps (0.4 mg, 0.6 mg, 0.8 mg, 1 mg), with a minimum of two weeks at each step, and only if your energy is good and the dose is fully tolerated [1].

Two weeks per step is the minimum, not the target. Move up only if your energy is good and you are not suffering the crash described further down. If a step brings on tiredness or a crash, stay on that dose, not the next one, until you feel entirely normal on it, and only then think about moving up. These figures are Body Pharm product guidance and a summary of off-label research and clinic practice; they are not medical advice and not an authorised dosing standard [1][4][5]. Anyone combining substances on the mitochondrial pathway can consult NAD+ dosing for the comparative planning logic.

Timing around training and the crash rule

The majority of people who use it place the MOTS-c injection around 30 minutes before training. The surge of energy arrives during the session, exactly when it is wanted.

What you need to watch for comes afterwards. If you have good energy for the workout and then, 3–4 hours later, you suffer a heavy crash, that crash is the sign that your body has not yet adjusted to the dose. It is not a reason to push through or to go higher: it is precisely the opposite. If you suffer that crash:

• Do not raise the dose. Stay exactly where you are.
• Hold that dose until the crash disappears and you feel normal on it all day long, not only during the training session.
• Only once a dose gives you clean energy with no crash afterwards should you consider moving up by the next 0.2 mg step.

There are people who find their comfortable level at 0.6 mg or at 0.8 mg and never need 1 mg at all. The right dose is the highest step that you tolerate with stable energy and no crash, reached slowly, and not the top end of the range reached quickly.

Why 2–3 times a week: the pharmacodynamic rationale

MOTS-c is dosed 2–3 times a week, in practice on training days, around 30 minutes before the session, because the intermittent three-doses-a-week schedule is the one Reynolds et al. used in aged mice [3], and because clinic practice estimates that the AMPK activation produced by a single dose persists for 48–72 hours before the signalling returns to its baseline value [4]. Dosing every day would be redundant and potentially desensitising. Leaving at least 48 hours between injections preserves the energy-stress signal that AMPK is meant to mimic; that is the mechanism through which the peptide was characterised in Lee's original 2015 work in mouse models [2]. Whatever your dose on the titration ladder, the every-other-day spacing does not change; it is the dose that gets titrated, not the frequency.

The pharmacodynamic logic is fairly straightforward. MOTS-c intervenes in the folate cycle and in purine biosynthesis, raises AICAR and triggers the phosphorylation of AMPK. That higher-order energy-sensor response then drives, downstream, mitochondrial biogenesis and the changes in insulin sensitivity [2]. Because those transcriptional and metabolic effects accumulate over a period of days, dosing on top of an already active AMPK pool adds little signal and risks blunting the receptor response. No published study has resolved this activation window to the hour with clinical precision, so that the 48–72 hour estimate is extrapolated from endpoint assays with repeated dosing in rodents, and not from human PK/PD (pharmacokinetic/pharmacodynamic) curves [2][3].

The published preclinical models have used both daily [2] and intermittent three-times-a-week [3] schedules; neither compared the two frequencies directly, so the advantage of spacing is a practice convention, not a comparative finding [4].

Comparison with daily-dosed peptides

MOTS-c differs from peptides such as BPC-157, which act on local tissue-repair pathways with short biological half-lives and for that reason benefit from administration once or twice a day. MOTS-c is a systemic metabolic signal, not an active compound for the wound site, so that its frequency follows the reset time of the downstream pathway, and not the plasma half-life.

Why 4 weeks on and 2 weeks off

Clinic practice describes a declining metabolic response after around four weeks of uninterrupted dosing [4]. That is the rationale for periodising the protocol with a 2-week washout phase. The rest window allows AMPK sensitivity and the mitochondrial transcriptional machinery to reset before the next cycle.

Anyone comparing the planning logic across substances on the mitochondrial pathway can consult NAD+ Dosing; anyone putting together tissue-repair combinations can read GHK-Cu Dosing for comparison.

Preparing the pen for injection

The Body Pharm MOTS-c pen comes pre-filled and ready to use. The dial sets directly the doses you titrate through, 0.2, 0.4, 0.6, 0.8 and 1 mg, so that at the point of use there is nothing to prepare, nothing to dilute and nothing to calculate; you simply dial the step you are on.

Follow the sequence below in a clean area and with washed hands:

1. Get the materials ready: the multi-dose pen, a new pen needle and alcohol wipes.
2. Bring the pen to temperature. Take it out of the fridge and let it come up to room temperature before you inject.
3. Clean the septum of the cartridge with an alcohol wipe and allow it to dry for around 30 seconds before screwing on the needle.
4. Check the solution. It should be clear and colourless; discard the pen if any cloudiness or particles appear.
5. Prime. Dial a small test dose and press until a droplet forms at the tip of the needle.
6. Dial the dose you are on (starting at 0.2 mg) and check the number on the dial at eye level.

Pen setting reference

The pen is set directly to whichever titration step you are on; you never have to convert a dose into a volume by hand:

Turn the dial up one step only if the current step is fully tolerated and gives you clean energy with no crash afterwards. Anyone combining it with mitochondrial cofactors can consult the pen handling in the NAD+ Dosing guide, and anyone working in parallel with the copper peptide should consult GHK-Cu Dosing for the compatibility guidance.

Subcutaneous injection technique and site rotation

Subcutaneous (SC) injection into the fatty tissue of the abdomen or thigh is the dominant route of administration for MOTS-c in the research protocols closest to human use; in the preclinical rodent work the route was intraperitoneal [2][3]; the pen and clinic practice use the subcutaneous route [4]. SC administration offers a slower and more even absorption than IM (intramuscular) administration and fits the pen-based workflow that the majority of researchers use in 2026.

Described parameters for the skin fold and the injection

1. Site preparation. The protocols describe cleaning the site with a 70% isopropyl wipe and letting it dry completely.
2. Skin fold. The usual practice is to lift a 2–3 cm fold of skin and subcutaneous fat between thumb and forefinger.
3. Needle angle. The angles described are 90° for a 4–6 mm pen needle, or 45° if a longer 8 mm needle is used at a lean site.
4. Delivery speed. The literature describes pressing the pen plunger slowly over 5–10 seconds.
5. Dwell time. According to the reports, holding for 10 seconds before withdrawing prevents backflow along the needle track.
6. Withdrawal. The protocols describe releasing the skin fold and pressing gently with dry gauze; massaging the site is not recommended.

Body Pharm pen cartridges are compatible with standard pen needles (30–32 G, 4–6 mm), the de facto standard for subcutaneous peptide injections in adults [4].

Site rotation plan

Rotating between at least four to six distinct sites per weekly plan prevents lipohypertrophy, the fibro-fatty thickening that develops when you inject repeatedly into one and the same spot and that increasingly distorts the kinetics of absorption.

Keep a simple rotation log (date, site, dose, batch) so that no site receives another injection within a 7–10 day period. Anyone applying substances on the mitochondrial pathway in parallel should keep separate site lists for each peptide; the same rotation logic applies to the NAD+ Dosing and GHK-Cu Dosing workflows.

MOTS-c cycles: 4 weeks on, 2 weeks off

A cycle of 4 active weeks and 2 weeks off is, in 2026, the best-supported periodisation framework for MOTS-c in research. Clinic practice describes the metabolic response reaching a plateau after around four weeks of continuous administration, which is attributed to adaptation of the AMPK pathway [4]. The 2-week washout phase allows signal sensitivity to reset before the next block of exposure.

As of 2026 there is no published human RCT at all on MOTS-c cycling. The periodisation logic set out below is extrapolated from preclinical patterns of continuous versus intermittent dosing in mouse models and from clinic practice schedules with 8–12 week windows [2][3][4].

A standard 12-week research window

Alternative: a single 8-week block

Anyone with endpoints on longer intervals (for example HbA1c, repeat VO₂max, body-composition imaging) usually prefers a single active block of 8 weeks followed by 4 weeks off. That concentrates the exposure into one continuous window, which simplifies attribution with a single before-and-after pair of measurements, at the cost of the internal reset that a two-cycle design offers.

The length of the cycle should follow the research question, not the other way round. Short studies on metabolic flexibility fit cleanly into the 4/2 pattern; questions about mitochondrial biogenesis or endurance adaptation may justify the 8/4 structure. Parallel pathway work with NAD+ or GHK-Cu should be cycled on independent schedules in order to isolate the variables.

Storage, handling and expiry

Store the pen between 2 and 8 °C and protected from light. Unopened, the shelf life is 24 months. Once the cartridge has been punctured for the first time, the pen is used up within a period of 12 months. If you do not have a fridge available, it remains stable at room temperature for a maximum of 30 days, without exceeding 30 °C. Bring the pen up to temperature before injecting and never freeze it: freeze-thaw cycles cause aggregation and a loss of bioactivity in small peptides. As of 2026 the published stability data specific to MOTS-c remain limited, so that these figures reflect the manufacturer's guidance and the standard practice for handling peptides, not studies specific to the substance.

Storage table for quick reference

Pen handling and hygiene

Work clean at every injection: wipe the septum with alcohol, fit a new needle and keep the number of punctures to a minimum in order to limit microbial ingress and coring particles. Keep the multi-dose pen refrigerated between uses, with the cap on and the needle removed after each injection, to avoid capillary leakage and air ingress.

Anyone running parallel protocols with NAD+ or GHK-Cu should label each pen unambiguously. Mix-ups in the fridge are a frequent and avoidable protocol error.

MOTS-c combinations: the ones worth knowing in research

MOTS-c is studied above all alongside other peptides aimed at the mitochondria or at longevity, where the mechanistic pathways are complementary rather than overlapping. As of 2026 no completed human study has formally characterised the pharmacokinetic interactions between MOTS-c and a co-administered peptide, so that every decision about a combination remains a matter of research design and not a therapeutic recommendation.

Combinations documented in research

MOTS-c + NAD+ (or NMN/NR precursors). The logic is one of parallel mitochondrial support: MOTS-c activates AMPK and shifts substrate use towards oxidative metabolism, while NAD+ precursors restore sirtuin-dependent signalling and the cofactor pools of the electron transport chain. No published preclinical study from 2024–2026 has formally evaluated simultaneous administration, so that any claim of synergy remains hypothetical. Consult the NAD+ Dosing guide for compatible planning.

MOTS-c + GHK-Cu. Researchers combine them when the question spans metabolic resilience and tissue-repair signalling, since GHK-Cu modulates copper-dependent remodelling pathways that lie outside the AMPK axis on which MOTS-c acts. The protocol guidance is in the GHK-Cu Dosing guide.

MOTS-c + humanin. Both of them are peptides of mitochondrial origin, and their combination is discussed in clinic practice because of their overlapping retrograde signalling, although we have not identified any published preclinical study of co-administration [4].

MOTS-c + CJC-1295/ipamorelin or SS-31. These appear in formative peptide protocols as "peak performance" combinations that bring together support aimed at the GH axis or at cardiolipin with the energy-sensor activation that MOTS-c provides [4].

Change only one variable at a time if the goal is data that can be attributed.

Frequently Asked Questions about MOTS-c dosing

The questions below summarise the dosing variables that researchers raise most often when working with MOTS-c in 2026. All of the answers reflect off-label research and clinic practice, not an authorised therapeutic regimen.

How much MOTS-c should I take?

Start with 0.2 mg per injection for the first two weeks, so that the body gets used to the product, and then titrate in 0.2 mg steps (0.4, 0.6, 0.8, 1 mg) with a minimum of two weeks at each step. Move up only if your energy is good and the current dose is fully tolerated. A lot of people find their comfortable level at 0.6–0.8 mg and never need 1 mg at all; the right dose is the highest step you tolerate with stable energy and no crash, reached slowly.

What if I crash after training?

That crash is the key signal that you need to watch for. If you have good energy for training and then, 3–4 hours later, you suffer a heavy crash, your body has not yet adjusted to the dose. Do not go up: hold that dose until the crash disappears and you feel normal on it all day long. Only once a dose gives you clean energy with no crash afterwards should you move up by the next 0.2 mg.

Can MOTS-c be dosed daily?

Daily dosing is not the standard at any step of the ladder. MOTS-c activates AMPK as an energy-deficit mimetic, and clinic practice assumes that the downstream mitochondrial signalling persists for 48–72 hours, which makes daily administration redundant in the majority of research designs [4]; the intermittent three-doses-a-week schedule is the one Reynolds et al. used in aged mice [3]. Leave at least 48 hours between injections, in practice on training days, whatever titration step you are on.

How long does a MOTS-c cycle last?

The usual cycles run for 4 active weeks followed by a 2-week washout phase, repeatable up to three times a year [4]. Within an active block, you hold or raise your titration step according to tolerance; you do not go back to 0.2 mg after each washout, unless a long break means you need to get used to it again. Coordinate the cycle planning with NAD+ Dosing if you are running mitochondrial support in parallel.

What needle gauge works for subcutaneous MOTS-c injection?

Standard 30–32 G, 4–6 mm pen needles are the reference gauge for subcutaneous pen administration into the abdomen and thigh in adults [1][4]. They deposit reliably in the subcutaneous layer and reduce discomfort over cycles lasting several weeks. The same gauges serve the GHK-Cu Dosing protocols.

Is MOTS-c the same as humanin?

No. MOTS-c and humanin are distinct peptides of mitochondrial origin, encoded in the mitochondrial genome, with different amino acid sequences and with downstream pathways that partially overlap but nonetheless remain separate. MOTS-c activates mainly AMPK through interference in the folate cycle, whereas humanin acts through cytoprotective receptor signalling. Their combination is discussed in clinic practice because of the overlapping retrograde signalling, with no published preclinical study of co-administration identified [4].

Research notice and regulatory context

MOTS-c is sold solely for the purposes of research and analysis and, as of 2026, it is not authorised for use in humans. It is not an authorised medicine and it holds no authorisation for any indication [5].

Body Pharm products are supplied solely for in vitro and laboratory research and are not intended for human consumption. This guide is not medical advice and it does not constitute a regimen for human use. Anyone working in parallel on the mitochondrial pathway with NAD+ Dosing or GHK-Cu Dosing is subject to the same regulatory framework.

Next steps

Planning a research protocol with MOTS-c usually begins by defining the primary endpoint (metabolic flexibility, mitochondrial biogenesis, endurance capacity or another). The cycle structure (4/2 or 8/4) follows from the measurement interval of that endpoint, with a site-rotation log and a storage log defined before the first injection. For anyone combining MOTS-c with complementary substances on the mitochondrial pathway, the NAD+ Dosing and GHK-Cu Dosing guides help to coordinate the planning and to avoid overlapping variables. Documenting every dose, every injection site and every date for the whole duration of the study supports reproducibility and informs future adjustments to the protocol.

Sources

1. Body Pharm dosing protocol for the MOTS-c pen (supplier specification, reviewed October 2026). Supplier research protocol, not a peer-reviewed study.
2. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. pubmed.ncbi.nlm.nih.gov/33473109
4. Clinic and supplier practice literature on MOTS-c (2023–2025), with no published controlled trial. Cited as practice convention, not as evidence.
5. Directive 2001/83/EC, Article 1: definition of a medicinal product by presentation and by function; consolidated text on EUR-Lex. eur-lex.europa.eu — legal basis for a reagent labelled "for research use only" remaining subject to pharmaceutical regulation if it is presented for human use.